Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa in gastric or rectal cancer undergoing chemoradiation
NCT00036400Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2001
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial in anemia comparing Epoetin Alfa with Placebo (2 arms). Primary endpoint: Number of red blood cell transfusions at 16 weeks. Started Dec 2001; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00036400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036400.